ArticleFrontiers in immunology2024

Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.

Xueyan Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.